U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...

Reports Q4 revenue $1.29B, consensus $1.25B. “Ventas (VTR) delivered strong financial performance and growth in the fourth quarter and full ...

You can choose an item below to see the year by year change or search for all items in the table below the chart. Construction of new homes is becoming more expensive because of the rising costs ...

Gerdau S/A Ord-1.93% R$35.34B ...